康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

已收盘 03-24 16:08:20

120.000

+7.900

+7.05%

最高120.800	最低112.400	成交量830.88万
今开113.700	昨收112.100	日振幅7.49%
总市值1,105亿	流通市值1,105亿	总股本9.21亿
成交额9.73亿	换手率0.90%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":120,"timestamp":1774339700008,"preClose":112.1,"halted":0,"volume":8308793,"delay":0,"changeRate":0.07047279214986625,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"已收盘","change":7.9,"latestTime":"03-24 16:08:20","open":113.7,"high":120.8,"low":112.4,"amount":973219338,"amplitude":0.074933,"askPrice":120,"askSize":29000,"bidPrice":119.9,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":112.1,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":1.191389,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6977,"impliedVolPercentile":0.9318},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0540923850.HKD","IE00B543WZ88.USD","BK1593","LU1770034418.SGD","09926","LU0307460666.USD","LU0348767384.USD","LU2399975544.HKD","BK1583","LU2476274308.USD","CXO","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD","LU1719994722.HKD","LU2328871848.SGD","02367","BK1585","BK1588","BK1197","BK1500","06160","IE00BPRC5H50.USD","03933","09688","LU0348766576.USD","LU0417516571.SGD","BK1191","01789","BK1207","LU0348735423.USD","06821","LU2778985437.USD","LU1115378108.SGD","LU0348827113.USD","02228","LU2488822045.USD","LU1794554557.SGD","01530","BK1141","LU0417516738.SGD","BK1574","03329","02196","BK1617","LU1303224171.USD","01099","02268","LU2476274720.SGD"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0708995583.HKD","SG9999014674.SGD","BK4585","LU1969619763.USD","02359","06881","02268","399441","LU0417516571.SGD","LU0307460666.USD","LU0348767384.USD","06990","LU1770034418.SGD","LU2778985437.USD","HK0000306685.HKD","XBI","LU0052750758.USD","HK0000320223.HKD","LU2242644610.SGD","LU2476274720.SGD","BK1147","BK1161","BK4581","BK1588","IE00B543WZ88.USD","LU2125910500.SGD","LU0348825331.USD","02696","LU0348766576.USD","BK4588","601881","BK1564","LU2328871848.SGD","LU0348735423.USD","LU2476274308.USD","09995","LU0540923850.HKD","09926","HK0000306701.USD","BK1141","06160","161726","LU2045819591.USD","LU0196878994.USD","LU0588546209.SGD","LU1720050803.USD","02162","BK0276"],"gpt_icon":0},{"id":"2619433428","title":"港股康方生物再涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619433428","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619433428?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:39","pubTimestamp":1773632358,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月16日，康方生物(09926.HK)再涨超4%，截至发稿涨4.26%，报114.9港元，成交额5.29亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163672903761.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163672903761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU0540923850.HKD","IE00B543WZ88.USD","LU0348783233.USD","09926","LU0348767384.USD","LU2399975544.HKD","LU2476274308.USD","BK4585","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD","BK4588","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0561508036.HKD","LU1720050803.USD","VXUS","LU0348735423.USD","LU2778985437.USD","LU0348827113.USD","LU2488822045.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348825331.USD","BK1574","LU2476274720.SGD"],"gpt_icon":0},{"id":"2619375433","title":"港股异动 | 康方生物(09926)再涨超4% 公司首款三抗AK150近日获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2619375433","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619375433?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:22","pubTimestamp":1773631347,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)再涨超4%，截至发稿，涨4.26%，报114.9港元，成交额5.29亿港元。消息面上，近日，康方生物宣布其三特异性抗体新药AK150获得NMPA临床试验默示许可，用于治疗晚期恶性实体瘤。AK150是康方生物基于AI制药研发技术平台和Tetrabody多抗技术平台开发的一款全球首创的ILT2/ILT4/CSF1R三抗，也是康方生物首个进入临床阶段的三抗新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","LU2399975544.HKD","LU0540923850.HKD","LU2476274720.SGD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU0417516571.SGD","LU2488822045.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU1961090484.USD","BK4588","LU0634319403.HKD","IE00B543WZ88.USD","LU0348784397.USD","LU2476274308.USD","LU0348827113.USD","LU0561508036.HKD","LU0348766576.USD","BK4585","LU0348767384.USD","BK1161","LU2778985437.USD","09926","LU1794554557.SGD","LU0417516902.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2618923825","title":"康方生物03月11日主力净流出492.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618923825","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618923825?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216923,"startTime":"0","endTime":"0","summary":"03月11日, 康方生物股价跌0.09%，报收114.90元，成交金额5.9亿元，换手率0.55%，振幅3.65%，量比0.47。康方生物今日主力资金净流出492.9万元，上一交易日主力净流入2.0亿元。该股近5个交易日上涨20.57%，主力资金累计净流入1.7亿元；近20日主力资金累计净流入1.1亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161626a6b7863a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161626a6b7863a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","BK1161","LU0348783233.USD","LU0540923850.HKD","LU2488822045.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU0348766576.USD","LU1794554557.SGD","LU1720050803.USD","LU2476274308.USD","LU0348735423.USD","BK1574","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2778985437.USD","LU2476274720.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2618238149","title":"康方生物三抗登场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618238149","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618238149?lang=zh_cn&edition=full","pubTime":"2026-03-11 10:09","pubTimestamp":1773194940,"startTime":"0","endTime":"0","summary":"近日，康方生物宣布其全球首创的ILT2/ILT4/CSF1R三特异性抗体新药AK150获NMPA临床试验默示许可，用于治疗晚期恶性实体瘤，这也是康方生物首个进入临床阶段的三抗新药。AK150可协同靶向三个靶点，多角度解除免疫抑制，临床前动物模型显示其有肿瘤抑制作用。康方生物是抗体领域全球领先的创新药企，建立了多个技术为核心的研发创新体系，已有27个候选药进入临床。此前，其全球首创的PD-1/CTLA-4、PD-1/VEGF双抗已获批上市，此次AK150获批临床是公司在抗体领域的又一重大突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031110114597ace027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031110114597ace027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU0348783233.USD","IE00BPRC5H50.USD","09926","LU0561508036.HKD","LU0348827113.USD","BK1574","LU0348784397.USD","LU0417516902.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU1961090484.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","LU2778985437.USD","LU0417516571.SGD","LU0348766576.USD","LU0348825331.USD","LU0348767384.USD","LU2399975544.HKD","LU0348735423.USD","LU0417516738.SGD","BK1161","LU1794554557.SGD","LU0540923850.HKD","LU0634319403.HKD"],"gpt_icon":0},{"id":"1107973285","title":"港股异动 | 创新药概念股普涨，康方生物、科伦博泰生物涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107973285","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107973285?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:58","pubTimestamp":1773107886,"startTime":"0","endTime":"0","summary":"3月10日，创新药概念股走强，$康方生物(09926)$、$科伦博泰(06990)$生物涨超9%，$三生制药(01530)$、$亚盛医药(AAPG)$、$康诺亚(02162)$涨超5%，$海西新药(02637)$涨近4%","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU2778985437.USD","BK1574","LU0348767384.USD","BK1161","LU0417516902.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348784397.USD","06990","BK4588","LU2476274308.USD","LU1720050803.USD","LU0417516738.SGD","LU0540923850.HKD","LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU2399975544.HKD","LU0348783233.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0417516571.SGD","BK4585","LU0348827113.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2618011096","title":"港股异动 | 康方生物(09926)早盘涨近8% 全球首创的三特异性抗体新药AK150进入临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2618011096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618011096?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:40","pubTimestamp":1773106838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)早盘涨近8%，截至发稿，涨7.33%，报111.3港元，成交额2.76亿港元。消息面上，康方生物全球首创的三特异性抗体新药AK150（ILT2/ILT4/CSF1R三抗）获得国家药品监督管理局药品审评中心临床试验默示许可批准，开展用于治疗晚期恶性实体瘤的临床试验。公开资料显示，AK150是全球唯一在研的ILT2/ILT4/CSF1R三抗，也是康方生物首个进入临床阶段的三抗新药。AK150是康方生物基于领先的AI制药研发技术平台和Tetrabody多抗技术平台而开发的全球首创新药，是公司在多特异性抗体技术领域强劲实力的又一次见证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","LU0348784397.USD","LU0561508036.HKD","LU2778985437.USD","LU1794554557.SGD","BK4585","LU0540923850.HKD","BK1574","LU2399975544.HKD","BK4588","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","LU0348766576.USD","LU2476274308.USD","LU0348767384.USD","BK1161","LU1720050803.USD","LU2476274720.SGD","LU2488822045.USD","LU0348735423.USD","IE00BPRC5H50.USD","VXUS","LU0417516902.SGD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU0348825331.USD","09926","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2618622203","title":"全球唯一！康方生物三抗获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2618622203","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618622203?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:09","pubTimestamp":1773050964,"startTime":"0","endTime":"0","summary":"3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。作为国内抗体药物研发的领军企业之一，康方生物已建立起丰富的产品管线。AK150的临床获批，不仅是康方生物技术平台能力的体现，也标志着国产创新药在多功能抗体领域正加速追赶全球前沿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348825331.USD","LU2778985437.USD","BK1574","LU0348767384.USD","BK1161","LU0417516902.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348784397.USD","LU2476274308.USD","LU1720050803.USD","LU0417516738.SGD","LU0540923850.HKD","LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU2399975544.HKD","LU0348783233.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0417516571.SGD","LU0348827113.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2618243622","title":"每日卖空追踪 | 康方生物 03月09日卖空量成交96.5万股，卖空比例为11.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618243622","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618243622?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045042,"startTime":"0","endTime":"0","summary":"康方生物北京时间03月09日，跌3.36%，卖空量成交96.5万股，较上一交易日减少27.61%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163626a45aea51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163626a45aea51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348783233.USD","LU2476274308.USD","LU0348825331.USD","LU1720050803.USD","LU1794554557.SGD","LU2399975544.HKD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","BK1161","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0417516571.SGD","LU1961090484.USD","LU0348767384.USD","LU2488822045.USD","LU0348784397.USD","09926","BK1574","LU0348827113.USD","LU2778985437.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU0634319403.HKD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2618617104","title":"康方生物盘中异动 急速跳水5.22%报101.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618617104?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:30","pubTimestamp":1773019844,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时30分，康方生物股票出现波动，股价急速下跌5.22%。截至发稿，该股报101.700港元/股，成交量48.9万股，换手率0.05%，振幅1.77%。资金方面，该股资金流入1098.26万港元，流出2070.99万港元。机构评级方面，在所有15家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。康方生物股票所在的生物技术行业中，整体跌幅为1.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909304497aa998e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909304497aa998e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516738.SGD","BK1161","LU0348735423.USD","LU0348766576.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU1794554557.SGD","LU2778985437.USD","LU0348827113.USD","09926","LU0348767384.USD","LU1961090484.USD","LU2476274308.USD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU0348825331.USD","LU0417516571.SGD","LU2476274720.SGD","LU0561508036.HKD","BK1574","LU1720050803.USD","LU0348783233.USD","LU0634319403.HKD","LU0348784397.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2618617106","title":"国产创新药持续发力，AD治疗领域将迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617106","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618617106?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:29","pubTimestamp":1773019791,"startTime":"0","endTime":"0","summary":"据悉，继司普奇拜单抗之后多款国产药物也加速推进临床，并将迎来一波上市高潮。未来随着这些产品的获批上市，AD药物领域将迎来新的用药选择。随着多款新药的陆续上市，这不仅将打破国外药物垄断、降低患者用药成本，更将推动我国AD治疗的发展。未来，在政策支持与企业创新的双重驱动下，国内AD药物研发将持续突破，为全球特应性皮炎治疗贡献中国力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348767384.USD","09926","06978","LU2488822045.USD","LU0417516902.SGD","01276","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2476274308.USD","BK1574","LU0348783233.USD","LU2778985437.USD","LU0634319403.HKD","LU0417516738.SGD","LU0417516571.SGD","00867","LU0348784397.USD","LU2476274720.SGD","LU1720050803.USD","LU0561508036.HKD","LU1961090484.USD","LU0348766576.USD","02162","BK1161","LU0348825331.USD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU2399975544.HKD"],"gpt_icon":0},{"id":"2617919503","title":"【券商聚焦】交银国际：医药公司业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617919503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617919503?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:08","pubTimestamp":1772759313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，2026年以来，内资通过港股通持有医药股的比例呈现先降后升态势，当前水平与年初持平，外资持仓则有所提升。本周内资继续加仓创新药产业链和器械标的，外资则重点布局创新药企及CXO企业。年报季临近，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU2399975544.HKD","LU0348766576.USD","BK1585","LU1961090484.USD","LU1794554557.SGD","SG9999014674.SGD","SG9999004311.SGD","02268","LU0348783233.USD","LU0348735423.USD","LU0540923850.HKD","LU0348825331.USD","06160","03329","IE00B5MMRT66.SGD","01789","HK0000165453.HKD","BK1191","LU1303224171.USD","09939","BK1574","LU1115378108.SGD","LU1770034418.SGD","LU0561508036.HKD","LU0348784397.USD","BK1593","LU0417516571.SGD","BK1515","IE00BPRC5H50.USD","LU0348827113.USD","02196","01099","LU0588546209.SGD","159938","BK1207","LU2476274308.USD","09688","02228","LU2476274720.SGD","LU2778985437.USD","BK1197","LU1719994722.HKD","03933","BK1141","09926","LU2488822045.USD","LU0640798160.USD","01530","02367"],"gpt_icon":0},{"id":"2617050978","title":"康方生物、三生国健等，扎堆申报！","url":"https://stock-news.laohu8.com/highlight/detail?id=2617050978","media":"药通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617050978?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:32","pubTimestamp":1772710373,"startTime":"0","endTime":"0","summary":"近日，康方生物、三生国健等IL-4Rα抗体迎来新进展。除了康方生物、三生国健，国内已有多款国产IL-4Rα单抗进入上市冲刺阶段，形成了群雄逐鹿的竞争格局。其中，康诺亚/石药集团的司普奇拜单抗已获批上市；宝船生物/麦济生物的柯美奇拜单抗、康乃德的乐德奇拜单抗、智翔金泰的泰利奇拜单抗等也相继申报上市，各自将凭借差异化优势抢占市场先机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305210329a6a6d362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305210329a6a6d362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","LU0348783233.USD","LU0348735423.USD","LU0561508036.HKD","LU2476274720.SGD","LU0417516571.SGD","BK1587","LU2488822045.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0348827113.USD","LU0540923850.HKD","09926","LU1720050803.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","BK1574","02162","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU0417516902.SGD","LU2399975544.HKD","BK1583","LU2476274308.USD","LU0348766576.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2617595458","title":"港股异动 | 康方生物-B(09926)早盘涨超6% 联合美国INOVIO新型DNA药物探索胶质母细胞瘤创新治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2617595458","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617595458?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:36","pubTimestamp":1772678176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物-B早盘涨超6%，截至发稿，涨6.3%，报101.3港元，成交额3.43亿港元。消息面上，康方生物与INOVIO联合宣布，双方已达成一项合作协议，将与全球顶级肿瘤研究机构Dana Farber Cancer Institute以及全球领先医疗集团Mass General Brigham合作，共同探索康方生物全球首创PD-1/CTLA-4双特异性抗体卡度尼利联合INOVIO旗下DNA药物INO-5412针对胶质母细胞瘤的创新治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","LU0417516738.SGD","LU0634319403.HKD","BK4109","LU1720050803.USD","LU2488822045.USD","LU0348827113.USD","LU1961090484.USD","VT","LU0561508036.HKD","BK1574","IE00B543WZ88.USD","LU2399975544.HKD","LU0348766576.USD","BK4588","VXUS","BK4139","LU1794554557.SGD","LU0417516902.SGD","LU2476274308.USD","LU0348784397.USD","BK4585","LU2476274720.SGD","LU0348767384.USD","LU0417516571.SGD","BK1161","DNA","LU0348825331.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0540923850.HKD","LU2778985437.USD","IE00BPRC5H50.USD","09926","BK4121"],"gpt_icon":0},{"id":"1191158198","title":"港股异动 | 创新药概念股走强，科伦博泰生物-B、歌礼制药-B涨超7%，恒瑞医药、康方生物涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191158198","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191158198?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:32","pubTimestamp":1772677926,"startTime":"0","endTime":"0","summary":"3月5日，创新药概念股走强，$科伦博泰生物-B(06990)$、$歌礼制药-B(01672)$涨超7%，$恒瑞医药(01276)$、$康方生物(09926)$涨超6%","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be7091872f1e44aea2b2c791b8b6184f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU2097828805.USD","LU1961090484.USD","LU0405327494.USD","LU2289578879.USD","LU2580892789.USD","BK0196","IE00B543WZ88.USD","LU0359201885.HKD","LU0348827113.USD","LU1997245177.USD","BK1161","BK1574","LU0196878994.USD","LU2476274308.USD","BK0188","LU2097828631.EUR","LU2476274720.SGD","BK1515","LU0359202008.SGD","BK4588","LU2148510915.USD","BK0183","01672","LU2328871848.SGD","LU0417516738.SGD","LU1720050803.USD","LU1146622755.USD","BK1191","LU0348783233.USD","LU1580142542.USD","LU0348825331.USD","LU1794554557.SGD","LU1969619763.USD","LU2399975544.HKD","LU2488822045.USD","LU2778985437.USD","LU2580892862.HKD","BK0028","LU0348767384.USD","BK0012","IE00B5MMRT66.SGD","LU1023057109.AUD","LU0634319403.HKD","LU1997245094.SGD","LU2097828474.EUR","LU2495084118.USD","LU2543165471.USD","LU0417516571.SGD","LU0348735423.USD","LU1064130708.USD","LU0561508036.HKD","LU1781817850.SGD","06990","LU0348784397.USD","LU0417516902.SGD","LU0540923850.HKD","BK4585","LU0359201612.USD","BK0060","LU1997244956.HKD","LU2097828557.USD","LU0348766576.USD","LU1064131003.USD","LU1655091616.SGD","LU1328615791.USD","LU1820825898.SGD","LU2097828714.EUR","09926","IE00BPRC5H50.USD","LU1255011170.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"1107150570","title":"伊诺维奥制药与康方生物达成临床合作 共同推进胶质母细胞瘤创新联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1107150570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107150570?lang=zh_cn&edition=full","pubTime":"2026-03-04 21:06","pubTimestamp":1772629577,"startTime":"0","endTime":"0","summary":"伊诺维奥制药与康方生物宣布，双方已就一项针对胶质母细胞瘤（GBM）的新型联合疗法达成临床合作协议。此次合作旨在加速该创新疗法的研发进程，为胶质母细胞瘤患者探索新的治疗选择。\n胶质母细胞瘤是一种侵袭性强、预后较差的脑部恶性肿瘤，目前临床治疗选择有限，存在巨大的未满足医疗需求。两家公司计划通过联合各自的优势研发平台与技术，推动该联合疗法的临床开发，以期改善患者的生存预后。\n此次合作将结合伊诺维奥制药在免疫疗法领域的专长与康方生物在肿瘤创新药物开发方面的经验。双方期待通过资源整合与协同效应，加速这一重要治疗方案的开发步伐，为全球胶质母细胞瘤患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU2399975544.HKD","LU2476274720.SGD","BK4583","LU0348766576.USD","INO","BK4568","LU1961090484.USD","BK1574","LU0348783233.USD","LU2778985437.USD","LU0561508036.HKD","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU0634319403.HKD","09926","LU1794554557.SGD","LU0417516738.SGD","IE00B543WZ88.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0417516571.SGD","LU0348784397.USD","LU0348735423.USD","LU0540923850.HKD","BK1161","BK4139"],"gpt_icon":0},{"id":"2616417555","title":"康方生物科技2026年2月股份变动月报表","url":"https://stock-news.laohu8.com/highlight/detail?id=2616417555","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616417555?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:36","pubTimestamp":1772616991,"startTime":"0","endTime":"0","summary":"金吾财讯|康方生物科技于2026年3月4日提交了截至2026年2月28日的股份变动月报表。在法定/注册股本方面，康方生物科技的法定/注册股本总额为50,000美元，面值为0.00001美元，股份总数为5,000,000,000股，与上月相比无变化。本月内，康方生物科技未进行股份回购、权证发行、可换股票据等其他变动。综上所述，康方生物科技在本月的股份变动情况较为稳定，未出现重大变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182607a44ae2cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182607a44ae2cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348827113.USD","LU0348784397.USD","LU0561508036.HKD","LU2778985437.USD","LU1794554557.SGD","LU0540923850.HKD","BK1574","LU2399975544.HKD","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","LU0348766576.USD","LU2476274308.USD","LU0348767384.USD","BK1161","LU1720050803.USD","LU2476274720.SGD","LU2488822045.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU0348825331.USD","09926","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"1134522378","title":"康方生物（09926）2026年2月月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1134522378","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134522378?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:18","pubTimestamp":1772615916,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年3月4日披露2026年2月股份变动月报表。报告期为截至2026年2月28日，公司注册股本及已发行股份数量与上月相比均无变化。报告期末已发行普通股总数仍为921,143,176股，未出现任何新增发行、购回或注销股份。截至2026年2月28日，公司股本保持稳定，亦符合香港联合交易所对公众持股量的相关规定。本次月报由董事夏瑜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2616552575","title":"每日卖空追踪 | 康方生物 03月04日卖空量成交74.4万股，卖空比例为7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616552575","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616552575?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613042,"startTime":"0","endTime":"0","summary":"康方生物北京时间03月04日，跌4.27%，卖空量成交74.4万股，较上一交易日减少51.28%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163630a6a152db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163630a6a152db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348783233.USD","LU2476274308.USD","LU0348825331.USD","LU1720050803.USD","LU1794554557.SGD","LU2399975544.HKD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","BK1161","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0417516571.SGD","LU1961090484.USD","LU0348767384.USD","LU2488822045.USD","LU0348784397.USD","09926","BK1574","LU0348827113.USD","LU2778985437.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU0634319403.HKD","LU0417516738.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0386},{"period":"1month","weight":0.0275},{"period":"3month","weight":-0.0106},{"period":"6month","weight":-0.159},{"period":"1year","weight":0.6546},{"period":"ytd","weight":-0.008}],"compareEarnings":[{"period":"1week","weight":-0.0562},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.054},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0292},{"period":"ytd","weight":-0.0487}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":-0.021344},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}